Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 14.3B | 4.8% |
| Gross Profit | 12M | 99.9% |
| Cost of Revenue | 3.3M | 99.9% |
| Operating expense | 6.2M | 99.9% |
| Net Income | 4M | 99.9% |
| EBITDA | 4.9M | 99.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 104B | 4.5% |
| Total Liabilities | 62.3B | 1.4% |
| Total Equity | 42B | 9.4% |
| Shares Outstanding | 1.96B | 1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 6.66B | 82.8% |
| Cash from investing | -2.24B | 779.7% |
| Cash from financing | -5.21B | 39% |
EPS
Financial Highlights for Novartis in Q2 '25
Novartis reported a revenue of 14.3B, which is a 4.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 12M, marking a -99.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.3M, a -99.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 6.2M, showing a -99.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 4M, showing a -99.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 4.9M, showing a -99.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Novartis faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. A decline in EBITDA signals potential operational challenges or increased costs.
